Hemodynamic abnormalities following cardiac transplantation: relationship to hypertension and survival

Am Heart J. 1989 Aug;118(2):334-41. doi: 10.1016/0002-8703(89)90194-4.

Abstract

The prevalence and long-term implications of hemodynamic abnormalities seen at 1 year following orthotopic heart transplantation and their relationship to post-transplant hypertension were prospectively evaluated in 82 consecutive asymptomatic recipients taking cyclosporine and prednisone who underwent annual catheterization. Abnormal left ventricular end-diastolic pressure (LVEDP), ejection fraction (EF), and left ventricular end-diastolic pressure-volume ratio (R) were the most prevalent hemodynamic abnormalities (27%, 14%, and 23%, respectively, at 1 year). Patients with abnormal LVEDP or R had higher (p less than 0.05) mean systemic arterial pressure (MAP). During follow-up, hemodynamic abnormalities disappeared in some patients while they developed in some others. Transplant patients with abnormal LVEDP, EF, or R at 1 year who normalized at 2 years had a significant (p less than 0.05) decrease in MAP. Likewise, patients with normal LVEDP, EF, or R at 1 year who subsequently developed abnormalities had a significant (p less than 0.05) increase in MAP. The presence of hemodynamic abnormalities at 1 year was not associated with a poorer survival (mean follow-up 2.6 +/- 1.1 years). In summary, hemodynamic abnormalities in asymptomatic transplant recipients taking cyclosporine and prednisone appear to be related to the level of post-transplant hypertension and do not signify an adverse prognosis over the first 3 years.

MeSH terms

  • Adult
  • Biopsy
  • Blood Pressure / drug effects
  • Coronary Angiography
  • Cyclosporins / adverse effects
  • Cyclosporins / therapeutic use
  • Female
  • Heart Transplantation*
  • Hemodynamics* / drug effects
  • Humans
  • Hypertension / chemically induced
  • Hypertension / physiopathology*
  • Male
  • Myocardium / pathology
  • Postoperative Complications
  • Prednisone / therapeutic use
  • Prospective Studies

Substances

  • Cyclosporins
  • Prednisone